SAN
JOSE, Calif., July 29,
2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa"
or the "Company") (NASDAQ: ANIX), a biotechnology company focused
on the treatment and prevention of cancer, today announced a
presentation on its ovarian cancer CAR-T therapy clinical trial at
the International Gynecologic Cancer Society (IGCS) 2024 Annual
Global Meeting being held October 16-18,
2024, in Dublin,
Ireland.
The presentation, titled "Phase I Clinical Trial of Autologous
T-cells Genetically Engineered with a Chimeric Receptor to Target
the Follicle Stimulating Hormone Receptor (FSHR) in Recurrent
Ovarian Cancer (OVCA)," will be presented by the study's principal
investigator, Dr. Robert Wenham,
Chair of Gynecologic Oncology at Moffitt Cancer Center, Anixa's
collaboration partner.
About Anixa's CAR-T Approach (Follicle Stimulating Hormone
Receptor-Mediated CAR-T technology)
Anixa's chimeric antigen
receptor T-cell (CAR-T) technology approach is an autologous cell
therapy comprised of engineered T-cells that target the follicle
stimulating hormone receptor (FSHR). FSHR is found at
immunologically relevant levels exclusively on the granulosa cells
of the ovaries. Since the target is a hormone (chimeric endocrine)
receptor, and the target-binding domain is derived from its natural
ligand, this technology is known as CER-T (chimeric endocrine
receptor T-cell) therapy, a new type of CAR-T. Anixa's
FSHR-mediated CAR-T technology was developed by Jose R. Conejo-Garcia, M.D., Ph.D., Professor of
Immunology in the Department of Integrative Immunobiology at the
Duke University School of Medicine.
Anixa holds an exclusive world-wide license to the technology from
The Wistar Institute.
About Anixa Biosciences, Inc.
Anixa is a
clinical-stage biotechnology company focused on the treatment and
prevention of cancer. Anixa's therapeutic portfolio consists of an
ovarian cancer immunotherapy program being developed in
collaboration with Moffitt Cancer Center, which uses a novel type
of CAR-T, known as chimeric endocrine receptor T-cell (CER-T)
technology. The Company's vaccine portfolio includes vaccines being
developed in collaboration with Cleveland Clinic to prevent breast
cancer – specifically triple negative breast cancer (TNBC), the
most lethal form of the disease – and ovarian cancer, as well as
additional cancer vaccines to address many intractable cancers,
including high incidence malignancies in lung, colon, and prostate.
These vaccine technologies focus on immunizing against "retired"
proteins that have been found to be expressed in certain forms of
cancer. Anixa's unique business model of partnering with
world-renowned research institutions on all stages of development
allows the Company to continually examine emerging technologies in
complementary fields for further development and commercialization.
To learn more, visit www.anixa.com or follow Anixa on Twitter,
LinkedIn, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements are not statements of historical facts, but rather
reflect Anixa's current expectations concerning future events and
results. We generally use the words "believes," "expects,"
"intends," "plans," "anticipates," "likely," "will" and similar
expressions to identify forward-looking statements. Such
forward-looking statements, including those concerning our
expectations, involve risks, uncertainties and other factors, some
of which are beyond our control, which may cause our actual
results, performance or achievements, or industry results, to be
materially different from any future results, performance, or
achievements expressed or implied by such forward-looking
statements. These risks, uncertainties and factors include, but are
not limited to, those factors set forth in "Item 1A - Risk Factors"
and other sections of our most recent Annual Report on Form 10-K as
well as in our Quarterly Reports on Form 10-Q and Current Reports
on Form 8-K. We undertake no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by law.
You are cautioned not to unduly rely on such forward-looking
statements when evaluating the information presented in this press
release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download
multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-announces-presentation-on-its-ovarian-cancer-car-t-clinical-trial-at-the-international-gynecologic-cancer-society-2024-annual-meeting-302207803.html
SOURCE Anixa Biosciences, Inc.
